Tecosience Participates in Bio USA... Anticipating Overseas Expansion

[Asia Economy Reporter Hyungsoo Park] TegoScience, a cell therapy developer, announced on the 23rd that it participated in the '2022 BIO International Convention' (BIO USA) exhibition.

TegoScience engaged in partnering with numerous pharmaceutical and new drug development companies. They introduced the cell therapy product 'Kaloderm,' the clinical-stage rotator cuff cell therapies TPX-114 and TPX-115, as well as their CDMO services.

There was significant interest in TPX-115, an allogeneic cell therapy for partially torn rotator cuff disease that has completed domestic Phase 1/2 trials. They received technology transfer and local development cooperation proposals from U.S. companies and are preparing for detailed discussions. As an innovative new drug therapy with no existing treatments in the U.S., TPX-115 attracted inquiries from various industry stakeholders at BIO USA.

Kaloderm, which has sold over 400,000 units domestically over the past 17 years for treating second-degree burns and diabetic foot ulcers, also drew attention. The proven efficacy and safety caught the interest of industry insiders. TegoScience received approval and sales-related proposals from numerous U.S. and European new drug developers wishing to introduce Kaloderm.

A TegoScience representative said, "It was an opportunity to once again showcase our technological capabilities and product excellence to the world," adding, "We are now closer to entering overseas markets."

This content was produced with the assistance of AI translation services.